Myrbetriq FDA Approval History
FDA Approved: Yes (First approved June 28, 2012)
Brand name: Myrbetriq
Generic name: mirabegron
Dosage form: Extended Release Tablets
Company: Astellas Pharma Inc.
Treatment for: Overactive Bladder
Myrbetriq (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Development Timeline for Myrbetriq
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.